Machine learning predictions based on historical earnings data and price patterns
1-Day Prediction
+8.94%
$31.37
100% positive prob.
5-Day Prediction
+6.40%
$30.64
100% positive prob.
20-Day Prediction
+3.09%
$29.69
95% positive prob.
SEC 8-K filings with transcript text
Feb 11, 2026 · 100% conf.
1D
+8.94%
$31.37
5D
+6.40%
$30.64
20D
+3.09%
$29.69
qdel-202602110001906324false00019063242026-02-112026-02-11
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): February 11, 2026
(Exact name of Registrant as specified in its Charter)
Delaware 001-41409
87-4496285
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
9975 Summers Ridge Road, San Diego, California 92121 (Address of principal executive offices, including zip code) (858) 552-1100 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, $0.001 Par ValueQDELThe Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On February 11, 2026, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its fourth quarter and full year ended December 28, 2025 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on February 11, 2026 to discuss such results. A copy of the press release is furnished with this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1.
The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is furnished with this Form 8-K:
Exhibit NumberDescription of Exhibit 99.1Press release, dated February 11, 2026, reporting QuidelOrtho Corporation's financial results for its fourth quarter and full year ended December 28, 2025.
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: February 11, 2026
By:/s/ Joseph M. Busky Name:Joseph M. Busky Its:Chief Financial Officer
Nov 5, 2025
qdel-202511050001906324false00019063242025-11-052025-11-05
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): November 5, 2025
(Exact name of Registrant as specified in its Charter)
Delaware 001-41409
87-4496285
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
9975 Summers Ridge Road, San Diego, California 92121 (Address of principal executive offices, including zip code) (858) 552-1100 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, $0.001 Par ValueQDELThe Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On November 5, 2025, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its third quarter ended September 28, 2025 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on November 5, 2025 to discuss such results. A copy of the press release is furnished with this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1.
The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is furnished with this Form 8-K:
Exhibit NumberDescription of Exhibit 99.1Press release, dated November 5, 2025, reporting QuidelOrtho Corporation's financial results for its third quarter ended September 28, 2025.
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 5, 2025
By:/s/ Joseph M. Busky Name:Joseph M. Busky Its:Chief Financial Officer
Aug 5, 2025
qdel-202508050001906324false00019063242025-08-052025-08-05
PURSUANT TO SECTION 13 OR 15(d) OF THE
Date of Report (Date of earliest event reported): August 5, 2025
(Exact name of Registrant as specified in its Charter)
Delaware 001-41409
87-4496285
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.)
9975 Summers Ridge Road, San Diego, California 92121 (Address of principal executive offices, including zip code) (858) 552-1100 (Registrant’s telephone number, including area code) N/A (Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act: Title of each classTrading symbol(s)Name of each exchange on which registered Common Stock, $0.001 Par ValueQDELThe Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition.
On August 5, 2025, QuidelOrtho Corporation (“QuidelOrtho”) issued a press release announcing the financial results for its second quarter ended June 29, 2025 and will hold an earnings conference call at 2:00 p.m., Pacific Time, on August 5, 2025 to discuss such results. A copy of the press release is furnished with this Current Report on Form 8-K (“Form 8-K”) as Exhibit 99.1.
The information in this Form 8-K, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits. The following exhibit is furnished with this Form 8-K:
Exhibit NumberDescription of Exhibit 99.1Press release, dated August 5, 2025, reporting QuidelOrtho Corporation's financial results for its second quarter ended June 29, 2025.
104Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL Document.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 5, 2025
By:/s/ Joseph M. Busky Name:Joseph M. Busky Its:Chief Financial Officer
This page provides QuidelOrtho Corporation (QDEL) earnings call transcripts from SEC 8-K filings along with AI-powered predictions for post-earnings price movements. Our machine learning models analyze historical earnings data, pre-earnings price patterns, volume changes, and volatility to predict 1-day, 5-day, and 20-day returns after each earnings release.
Earnings transcripts are sourced directly from SEC EDGAR filings. Predictions are generated using gradient boosting models trained on QDEL's historical earnings reactions. All predicted returns are shown as percentages, and predicted prices are calculated from the closing price at the time of prediction. Past performance does not guarantee future results.